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I N T R O D U C T I O N
Cardiac arrest (CA) is defined as the sudden cessation of spontaneous circulation 
and ventilation. Unfortunately, survival rates of both out of hospital and in hospital 
cardiac arrest remain low and merely unchanged over the last 30 years. Cardiopulmo-
nary resuscitation (CPR) is an attempt to restore effective, spontaneous circulation 
and ventilation through a variety of interventions including early defibrillation, chest 
compressions, advanced airway management, pharmacological therapy and effective 
post-resuscitation treatment, once return of spontaneous circulation (ROSC) has 
been achieved. Both, European Resuscitation Council (ERC) and American Heart 
Association (AHA) have published detailed guidelines in an attempt to incorporate 
recent scientific advances in a variety of topics underpinning CPR.
The major concepts of these guidelines are the increased emphasis on high quality, 
minimally interrupted chest compressions of adequate rate and depth, avoidance of 
hyperventilation, early defibrillation for specific heart rhythms with minimization of 
the pre-shock pause and greater detail and importance on the treatment of the post-
cardiac arrest syndrome.
Pharmacologic interventions continue to be a fundamental part of advanced life 
support, although there are no clinical data indicating that any drug improves long 
term survival after CA. In addition, there is inadequate evidence to define the optimal 
timing, dose or order for drug administration. The primary goal of pharmacologic 
therapy during CA is to facilitate restoration and maintenance of a perfusing and 
spontaneous rhythm. Vasopressors and antiarrhythmics are the main drug categories 
used in CPR algorithms. Novel pharmaceutical approaches are on the way, some of 
them being promising for future use.
VA S O P R E S S O R S
To date no placebo controlled trial has shown that administration of any vasopres-
sor agent, at any stage during management of CA increases the rate of neurologically 
intact survival to hospital discharge, although there is evidence that they may improve 
ROSC and short term survival. Epinephrine and vasopressin are the most studied 
vasopressors in CA.
Epinephrine
Epinephrine administration has been advocated in resuscitation for decades and 
forms a key component of published guidelines. Its use is based chiefly on animal studies 
while human trial evidence is scant. Epinephrine is a powerful agonist of both a- and β- 
adrenergic receptors. It has been the vasopressor of choice because of its a
2
-adrenergic 
effects which cause systemic vasoconstriction, increase coronary and cerebral perfusion 
pressures and consequently the success of initial resuscitation. However, epinephrine 
has also β-adrenergic effects which increase myocardial oxygen consumption and the 
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AbbreviAtions
CA = cardiac arrest
CPR = cardiopulmonary resuscitation
ROSC = return of spontaneous 
circulation
VF = ventricular fibrillation
VT = ventricular tachycardia
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severity of post-resuscitation myocardial dysfunction. The 
β-adrenergic effects of epinephrine also account for increases 
in ventricular ectopy and recurrence of ventricular tachycardia 
or fibrillation. In addition, epinephrine produces arteriove-
nous shunting through the lungs and therefore causes a very 
profound although transient reduction in the arterial oxygen 
content. The optimal dose of epinephrine is not known and 
there are no data supporting the use of repeated doses. Simi-
larly, there are no data on the pharmacokinetics of epinephrine 
during CPR. The optimal duration of CPR and the number of 
shocks that should be given before administration of drugs is 
unknown. On the basis of expert consensus it is reasonable to 
consider administering 1mg dose of epinephrine IV/IO every 
3 to 5 minutes during adult CA. ERC guidelines suggest that 
the first dose should be given after the third shock for VF/
pulseless VT CA, once chest compressions have resumed, 
while AHA suggests that the first dose should be given after 
the second shock. Higher doses may be considered in special 
circumstances such as β-blocker or calcium channel blocker 
overdose or as indicated by hemodynamic monitoring. If the 
initial arrest rhythm is pulseless electrical activity (PEA) or 
asystole the administration of epinephrine is recommended 
as soon as vascular access is obtained.
Vasopressin
Vasopressin is a non-adrenergic naturally occurring va-
soconstrictor that activates V
1a
 receptors on arterial smooth 
muscle cells causing peripheral, coronary and renal vasocon-
striction. It remains active during tissue hypoxia and acidosis 
and lacks the drawbacks of β-adrenergic stimulation. Initial 
animal data suggested that vasopressin might be more effec-
tive than epinephrine. Optimism was fueled by animal studies 
demonstrating that vasopressin versus epinephrine increased 
blood flow in vital organs, improved cerebral oxygen delivery 
and increased the probability of restoring spontaneous circula-
tion and neurologic outcome. However, vasopressin failed to 
show an equivocal benefit in humans. Delayed onset of action, 
prolonged vasoconstriction, increased heart afterload, negative 
inotropic effect and coronary vasoconstriction are possible 
components of the explanation. AHA recommends that one 
dose of vasopressin 40 IU IV/IO may replace the first or second 
dose of epinephrine in the treatment of VF/pulseless VT CA. 
Its use was not included in the ERC guidelines.
There are no alternative vasopressors or combination 
of vasopressors with proven survival benefit compared with 
epinephrine.
A N T I A R R H Y T H M I C S
There is no evidence that any antiarrhythmic drug given 
routinely during human cardiac arrest increases survival to 
hospital discharge.
Amiodarone
Amiodarone is a diverse antiarrhythmic drug with complex 
electrophysiological and pharmacological profile. It has mem-
brane stabilizing effects, increases duration of action potential 
and refractory period in atrial and ventricular myocardium 
and slows conduction in atrioventricular node and acces-
sory pathways. It also exerts a mild negative inotropic action 
and causes peripheral vasodilation through non-competitive 
α-blocking effects. Amiodarone may be considered for those 
who have refractory ventricular tachycardia (VT)/ ventricular 
fibrillation(VF), defined as VF/VT not terminated by defi-
brillation, or VF/VT reccurence in out-of or in-hospital CA. 
Following three initial shocks, amiodarone improves the short 
term outcome of survival to hospital admission compared with 
placebo or lidocaine. Amiodarone also appears to improve the 
response to defibrillation when given to humans or animals 
with VF or haemodynamically unstable VT. In the clinical 
studies to date amiodarone was given when VF/VT persisted 
after at least three shocks. For these reasons and in the absence 
of any other data it can be considered for treatment of VF or 
pulseless VT unresponsive to shock delivery, CPR and vaso-
pressors. An initial dose of 300mg I.V./I.O. can be followed 
by one dose of 150mg. Amiodarone should be available in all 
in-hospital and out-of-hospital cardiac arrests attended by 
emergency medical services.
Lidocaine
Lidocaine is an antiarrhythmic drug of long standing and 
widespread familiarity, which however has no proven short- or 
long term efficacy in CA. Comparative studies with amiodar-
one have proven the superiority of the first one and so lidocaine 
may be considered only when amiodarone is unavailable. The 
initial dose is 1-1.5mg/kg I.V. When VF pulseless VT persists 
additional doses of 0.5-0.75mg/kg I.V. push may be adminis-
tered at 5 to 10 minute intervals to a maximum dose of 3mg/kg.
Magnesium
Magnesium is an emerging antiarrhythmic agent that can 
be best classified as a sodium/potassium pump agonist. It 
blocks atrial L and T type calcium channels, prolongs both 
atrial refractory period and conduction, inhibits potassium 
entry and suppresses ventricular after depolarisations. Obser-
vational studies showed that magnesium can facilitate termi-
nation of Torsades de Pointes (TdP) (irregular/polymorphic 
VT associated with prolonged QT interval). Magnesium is 
not likely to be effective in terminating irregular/polymorphic 
VT in patients with normal QT interval. The benefit of giv-
ing magnesium routinely during CA is unproven. Studies in 
adults and in out of hospital CA have failed to demonstrate 
an increase in the rate of ROSC when magnesium is giving 
routinely during CPR. When VF/pulseless VT CA is associ-
ated with TdP providers may administer an I.V./I.O. bolus of 
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magnesium sulfate at a dose of 1-2gr peripherally over 1 to 2 
minutes. Dose may be repeated in 10 to 15 minutes. Special 
situations where administration of magnesium is indicated are 
hypomagnesaemia and digitalis toxicity.
O T H E R  D R U G S
There is no convincing evidence that the routine use of 
other drugs during human CPR increases survival to hospital 
discharge.
Atropine
No prospective controlled clinical trial has examined the 
use of atropine in asystole or bradycardic PEA cardiac arrest. 
Available data suggest that routine use of atropine during PEA 
or asystole is unlikely to have a therapeutic benefit, because 
CA is usually due to primary myocardial pathology rather 
than excessive vagal tone. For these reason atropine has been 
removed from the cardiac arrest algorithm and its routine use 
is no longer recommended.
Sodium bicarbonate
Routine administration of sodium bicarbonate for treat-
ment of in-hospital and out-of-hospital CA is not recom-
mended. Tissue acidosis and resulting acidemia during CA and 
resuscitation are dynamic processes resulting from no blood 
flow during arrest and low blood flow during CPR. Restoration 
of oxygen content with appropriate ventilation and support 
of tissue perfusion with high quality chest compressions until 
ROSC is achieved are the mainstays of restoring acid-base bal-
ance during CA. Special circumstances where administration 
of sodium bicarbonate can be considered are CA associated 
with hyperkalaemia and tricyclic antidepressants overdose.
Fibrinolysis
Fibrinolytic therapy should be considered, as an empiri-
cal therapy, when CA is caused by proven or suspected acute 
pulmonary emblolism. In these circumstances CPR should be 
performed for at least 60-90 minutes before termination of 
resuscitation attempts. Ongoing CPR is not a contraindication 
to fibrinolysis. Fibrinolytic therapy should not be routinely 
used in CA.
F U T U R E  P E R S P E C T I V E S
C O R T I C O S T E R O I D S
Early observational studies of the use of corticosteroids 
during CA suggested possible benefit. Recent study results 
indicate that hydrocortisone administration was related with 
significantly higher rate of ROSC but with no treatment benefit 
in terms of short term survival. There is insufficient evidence 
to support or refute the use of corticosteroids alone or in 
combination with other drugs during CA.
Β - B L O C K E R S
Beta-Blockade has been extensively studied in animal 
models of CPR (esmolol, atenolol). These studies not only 
suggest that beta-blockade could reduce myocardial oxygen 
requirements and the number of shocks necessary for defibril-
lation, but also improve post-resuscitation myocardial function, 
diminish arrhythmia recurrence and prolong survival. There 
are few case reports describing successful beta-blockade use in 
patients along with two prospective human studies suggesting 
that it could be safe and effectively used during human CA. 
Even though the existing literature points toward a beneficial 
effect of beta-blockade in patients presenting with CA due to 
VF/pulseless VT high quality human trials are still lacking to 
answer this question definitely.
E R Y T H R O P O I E T I N  ( E P O )
Besides its action as the principal hematopoietic hormone 
Epo exhibits diverse cellular effects in non hematopoietic 
tissues. Due to its anti-apoptotic, anti-inflammatory, anti-
oxidant properties, and its angiogenic action, Epo plays a role 
in neuroprotection and cardioprotection. Preliminary clinical 
data show that Epo given during CPR facilitates ROSC, ICU 
admission, 24hour-survival and hospital-survival as well as a 
trend towards better neurological recovery. Several clinical 
trials are in progress and hopefully will cover some knowledge 
gaps in the field. In this regard, Epo may represent a promising 
agent in the cardiac arrest setting.
I N O T R O P E S
Inotropes are currently recommended in post-resuscitation 
syndrome for treatment of myocardial dysfunction, despite 
the fear of aggravation of focal ischaemia and dependency. 
Levosimendan is a calcium sensitizing inotroping drug that 
lacks β-adrenergic effects and does not increase intracellular 
calcium. Animal data demonstrate that administration of levo-
simendan plus epinephrine during CPR significantly improves 
initial resuscitation success and increases coronary perfusion 
pressure and brain regional oxygen saturation in comparison 
to adrenaline plus placebo. Animal studies have also reported 
a synergistic action of levosimendan and β��loc�ers in im�rov�-b k p -
ing post-resuscitation myocardial function. Human trials are 
needed to establish the role of levosimendan in the CA setting.
O T H E R  A G E N T S
Sodium-hydrogen exchange inhibitors (cariporide), 
δ-opioid agonists (DADLE) and ATP sensitive potassium 
channel activators are new pharmaceutical modalities under 
investigation for future use in CPR, with preliminary and 
experimental data indicating a possible role.
18
HOSPITAL CHRONICLES 2010, VOLUME 7, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2012»
C O N C L U S I O N
Only a few drugs are indicated during the immediate 
management of CA and there is limited scientific evidence sup-
porting their use. Drugs should be considered only after initial 
shocks have been delivered -if indicated- and chest compres-
sions have been started. The evidence for the optimal timing 
and order of drug delivery and the optimal dose is limited. No 
interruptions should be made in chest compressions in order 
to give drugs. Current practice still supports adrenaline as the 
primary vasopressor for the treatment of CA of all rhythms. 
Amiodarone is the antiarrhythmic drug of choice in the CA 
setting. Better understanding of the pathophysiology of the 
cardiac arrest has allowed the exploration of novel pharma-
ceutical approaches in most cases in animal studies. High 
quality, randomized controlled trials are still lacking in the 
area in order these to be safely implemented in human CA.
